Recombinant Nerve Growth Factor anticorps

N° du produit ABIN7543389

L’anticorps Souris Monoclonal anti-Nerve Growth Factor a été validé pour ELISA, BP, Crys, in vitro, in vivo et Inh. Il convient pour détecter Nerve Growth Factor dans des échantillons de Humain.

Aperçu rapide pour Recombinant Nerve Growth Factor anticorps (ABIN7543389)

Antigène: Nerve Growth Factor (NGF)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Nerve Growth Factor est non-conjugé

Application: ELISA, Blocking Peptide (BP), Crystallization (Crys), In vitro Assay (in vitro), In vivo Studies (in vivo), Inhibition (Inh)

Clone: 911

Détail du produit anti-Nerve Growth Factor anticorps

Fonction: Anti-Nerve growth factor [mab 911], Mouse IgG1, kappa

Specificité: The antibody is specific for NGF. The NGF epitope is composed of β-strand segments from both NGF monomers. NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons).

Réactivité croisée: Souris

Attributs du produit:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Isotype: IgG1 kappa

Information d'application

Indications d'application: The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000, PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005, PMID: 15836976 and Halvorson et al., 2005, PMID: 16230406 and Buehlmann et al., 2019, PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007, PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM, under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014, PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced pain behaviour in osteoarthritis (Xu et al., 2016, PMID: 27208420).

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur Nerve Growth Factor

Antigène: Nerve Growth Factor (NGF)

Autre désignation: Nerve growth factor

Sujet: Beta-nerve growth factor, Beta-NGF

UniProt: P01138

Pathways: Regulation of Cell Size